Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: From the Canadian infections in AML research group

Pediatric Infectious Disease Journal

Volumn 33, Issue 2, 2014, Pages 126-129

  Lewis, Victor ^a   Yanofsky, Rochelle ^b   Mitchell, David ^c   Dix, David ^d   Ethier, Marie Chantal ^e   Gillmeister, Biljana ^e   Johnston, Donna ^f   Michon, Bruno ^g   Stobart, Kent ^h   Portwine, Carol ⁱ   Silva, Mariana ^j   Cellot, Sonia ^k   Price, Victoria ^l   Bowes, Lynette ^m   Zelcer, Shayna ⁿ   Brossard, Josee ^o   Beyene, Joseph ^p   Sung, Lillian ^e  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

^b Hematology/Oncology   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

ⁱ MCMASTER CHILDREN S HOSPITAL   (Canada)

^j Cancer Centre of Southeastern Ontario   (Canada)

^k UNIVERSITY OF MONTREAL   (Canada)

^l IWK HEALTH CENTRE   (Canada)

^m New Janeway Childrens Health and Rehabilitation Centre   (Canada)

ⁿ Hematology/Oncology   (Canada)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^p MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

acute myeloid leukemia; bacteremia; pediatric; viridans group streptococci

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; COHORT ANALYSIS; DEATH; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUTROPENIA; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STREPTOCOCCUS VIRIDANS INFECTION;

ANTI-BACTERIAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; BACTEREMIA; CANADA; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; RETROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; VIRIDANS STREPTOCOCCI;

EID: 84893025294     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000058     Document Type: Article

References (40)

1. G ibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;192130-2138
2. L ange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia a report from the children's oncology group. Blood. 2008;111 1044-1053
3. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia a report from the Children's Oncology Group. Cancer. 2012;118761-769
4. Majhail NS, Brazauskas R, Hassebroek A, et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012;18861-873
5. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia a report from the Children's Cancer Group. Blood. 1996;874979-4989
6. Cohen J, Donnelly JP, Worsley AM, et al. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet. 1983;21452-1454
7. Bochud PY, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer clinical spectrum and risk factors. Clin Infect Dis. 1994;1825-31
8. Feusner JH, Hastings CA. Infections in children with acute myelogenous leukemia. Concepts of management and prevention. J Pediatr Hematol Oncol. 1995;17234-247
9. R ichard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;3451607-1609
10. Bilgrami S, Feingold JM, Dorsky D, et al. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21591-595
11. Johnston DL, Lewis V, Yanofsky R, et al. Invasive fungal infections in paediatric acute myeloid leukaemia. Mycoses. 2013;56482-487
12. G amis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia a report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000;181845-1855
13. Marron A, Carratalà J, González-Barca E, et al. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000;311126-1130
14. Cordonnier C, Buzyn A, Leverger G, et al.; Club de Réflexion sur les Infections en Onco-Hématologie. Epidemiology and risk factors for gram-positive coccal infections in neutropenia toward a more targeted antibiotic strategy. Clin Infect Dis. 2003;36149-158
15. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;1103532-3539
16. G upta A, Singh M, Singh H, et al. Infections in acute myeloid leukemia an analysis of 382 febrile episodes. Med Oncol. 2010;271037-1045
17. Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia results from a multi-center Italian study. Pediatr Blood Cancer. 2010;551103-1107
18. R eilly AF, Lange BJ. Infections with viridans group streptococci in children with cancer. Pediatr Blood Cancer. 2007;49774-780
19. Persson L, Vikerfors T, Sjöberg L, et al. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis. 2000;32615-621
20. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States improvements to the 1977National Center for Health Statistics version. Pediatrics. 2002;10945-60
21. Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25696-703
22. Marron A, Carratalà J, Alcaide F, et al. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother. 2001;4787-91
23. G assas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;221222-1227
24. Martino R, Manteiga R, Sánchez I, et al. Viridans streptococcal shock syndrome during bone marrow transplantation. Acta Haematol. 1995;9469-73
25. Martino R, Subirá M, Manteiga R, et al. Viridans streptococcal bacteremia and viridans streptococcal shock syndrome in neutropenic patients comparison between children and adults receiving chemotherapy or undergoing bone marrow transplantation. Clin Infect Dis. 1995;20476-477
26. D ix D, Cellot S, Price V, et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML) results from the Canadian infections in AML research group. Clin Infect Dis. 2012;551608-1614
27. G oldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;62-8
28. L evy MM, Fink MP, Marshall JC, et al.; International Sepsis Definitions Conference. 2001 SCCMESICMACCPAT SSIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29530-538
29. Brunet AS, Ploton C, Galambrun C, et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006;47765-772
30. E lting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci a case-control study of predisposing factors. Clin Infect Dis. 1992;141201-1207
31. Weisman SJ, Scoopo FJ, Johnson GM, et al. Septicemia in pediatric oncology patients the significance of viridans streptococcal infections. J Clin Oncol. 1990;8453-459
32. E ngelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation a 5-year prospective study. Bone Marrow Transplant. 1995;16565-570
33. Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990;18138-145
34. R ossetti F, Cesaro S, Putti MC, et al. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol. 1995;12387-392
35. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14129-135
36. A rceci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol. 2002;9353-360
37. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113376-382
38. Westling K, Julander I, Ljungman P, et al. Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease. Clin Microbiol Infect. 2004;10899-903
39. Kennedy HF, Gemmell CG, Bagg J, et al. Antimicrobial susceptibility of blood culture isolates of viridans streptococci relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother. 2001;47693-696
40. Potgieter E, Carmichael M, Koornhof HJ, et al. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 1992;11543-546